TrialCold Spring Harbor molecular case studies2019

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with

Alexander Drilon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.